For example, the Immunoscore, which is based on quantification of CD3+/CD8+ lymphocyte heterogeneity at the core and boundary of tumors (54), can outperform traditional TNM staging in predicting disease-free survival and overall survival in colorectal cancer (54, 55) and other cancers (56, 57). This evidence concerns the gene CD8A and colorectal cancer.